cabergoline 中文意思是什麼

cabergoline 解釋
卡麥角林
  1. Patients treated with ergot derivatives who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades

    在服用麥角?生物進行治療的患者中，發生任何瓣膜3到4級返流的患者服用培高利特或卡麥角林的平均累積劑量顯著高於瓣膜返流級別較低的患者。
  2. Conclusions the frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non ? ergot - derived dopamine agonists, as compared with control subjects

    結論：與對照組相比，服用培高利特或者卡麥角林的患者臨床上發生重要瓣膜返流的頻率顯著增加，但服用非麥角?生的多巴胺受體激動劑的患者瓣膜返流的發生率卻未增加。
  3. Background case reports and echocardiographic studies suggest that the ergot - derived dopamine agonists pergolide and cabergoline, used in the treatment of parkinson ' s disease and the restless legs syndrome, may increase the risk of cardiac - valve regurgitation

    背景：病例報告和超聲心動圖研究提示，用於治療帕金森病和不寧腿綜合征的藥物?麥角?生物，多巴胺受體激動劑培高利特和卡麥角林，可能增加發生心臟瓣膜返流的風險。
  4. Methods we performed an echocardiographic prevalence study in 155 patients taking dopamine agonists for parkinson ' s disease ( pergolide, 64 patients ; cabergoline, 49 ; and non ? ergot - derived dopamine agonists, 42 ) and 90 control subjects

    方法：我們用超聲心動圖對155例正在服用多巴胺受體激動劑（ 64例服用培高利特， 49例服用卡麥角林， 42例服用非麥角?生的多巴胺受體激動劑）治療帕金森病的患者和90例對照組進行了一項流行調查。
  5. Results clinically important regurgitation ( moderate to severe, grade 3 to 4 ) in any valve was found with significantly greater frequency in patients taking pergolide ( 23. 4 % ) or cabergoline ( 28. 6 % ) but not in patients taking non ? ergot - derived dopamine agonists ( 0 % ), as compared with control subjects ( 5. 6 % )

    結果：與對照組相比（ 5 . 6 % ） ，服用培高利特（ 23 . 4 % ）或者卡麥角林的患者（ 28 . 6 % ） ，臨床上發生重要的任何瓣膜的返流（中到重度， 3級到4級）的頻率顯著升高，而服用非麥角?生的多巴胺受體激動劑的患者（ 0 % ）瓣膜返流的發生率卻未增加。
  6. Conclusions in this study, use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac - valve regurgitation

    結論：研究發現使用多巴胺受體激動劑培高利特和卡麥角林可增加新發生的心臟瓣膜返流的風險。
  7. Results of 31 case patients with newly diagnosed cardiac - valve regurgitation, 6 were currently exposed to pergolide, 6 were currently exposed to cabergoline, and 19 had not been exposed to any dopamine agonist within the previous year

    結果：有31例患者出現新診斷的心臟瓣膜返流，其中6例研究時正在服用培高利特， 6例使用卡麥角林，另外19例在研究的前一年中未再使用任何多巴胺受體激動劑。
分享友人
分享到 Line

分享到臉書